RADIUS HEALTH, INC. (NASDAQ:RDUS) Files An 8-K Other Events
On May 24, 2017, Radius Health, Inc. issued a press release
announcing positive top-line results from the completed 24 month
ACTIVExtend clinical trial of TYMLOS (abaloparatide) injection in
postmenopausal women with osteoporosis.A copy of the press
release is filed as Exhibit 99.1 and is incorporated herein by
Financial Statements and Exhibits.
Press Release dated May 24, 2017.
About RADIUS HEALTH, INC. (NASDAQ:RDUS)
Radius Health, Inc. is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer. RADIUS HEALTH, INC. (NASDAQ:RDUS) Recent Trading Information
RADIUS HEALTH, INC. (NASDAQ:RDUS) closed its last trading session up +0.21 at 37.37 with 975,050 shares trading hands.